Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Muhammet Rıdvan Tayşi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Health Ministry of Turkish Republic Konya City Hospital, Konya, Turkey. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Microbial Sensitivity Tests, Escherichia coli, Klebsiella Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
With the rise in antimicrobial resistance, there is a growing demand for rapid antimicrobial susceptibility testing (RAST). In this study, we applied the EUCAST RAST method to ESBL/carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolates without using advanced identification systems and analysed the effect of this method on mortality rates Also the clinical impact of this method on patients infected with these bacteria and its effect on mortality rates were investigated.
Methods
RAST was used for clinical blood cultures containing carbapenemase/ESBL-producing E. coli and K. pneumoniae without advanced identification systems (e.g. MALDI TOF), with preliminary identification by simple diagnostic tests (predicted RAST, or p-RAST), and its categorical agreement was investigated. The impact of the method on mortality was analysed by comparing the clinical data of patients whose blood cultures were subject to p-RAST (p-RAST group, n = 49) and those who were not subject to p-RAST (non-RAST group, n = 145). Results p-RAST results were analysed based on 539 antibiotic-bacteria combinations. Total error rates at 4, 6 and 8 h of incubation were 2.9%, 3.9% and 3.8%, respectively. In the p-RAST group, patients who did not receive appropriate antibiotics (29/45, 59.1%) were switched to appropriate treatment within 8 h at the latest. In contrast, in the non-RAST group, treatment of patients who received inappropriate antibiotics (79/145, 54.5%) could be changed after at least 24 h. Mortality rates were lower in the p-RAST group than in the non-RAST group (28.6% versus 51.7%, P = 0.005). Conclusions p-RAST can be used safely in hospital laboratories with high rates of antimicrobial resistance and can reduce mortality rates by shortening the transition time to appropriate treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Health Ministry of Turkish Republic Konya City Hospital, Konya, Turkey.
- Department of Medical Microbiology, Ankara University School of Medicine, Ankara, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Health Ministry of Turkish Republic Etlik City Hospital, Ankara, Turkey.
- Department of Microbiology, Gazi University School of Medicine, Ankara, Turkey.
ORCID-Profile: Muhammet Rıdvan Tayşi
Zitieren
APA
Tayşi, M. R., Öcal, D., Çiçek Şentürk, G., Çalişkan, E., Çelik, B., & Şencan, İ. (2024). Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae125
Vancouver
Tayşi MR, Öcal D, Çiçek Şentürk G, Çalişkan E, Çelik B, Şencan İ. Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae125
BibTeX
@article{Tayi2024,
author = {Tayşi, Muhammet Rıdvan and Öcal, Duygu and Çiçek Şentürk, Gönül and Çalişkan, Elif and Çelik, Bahar and Şencan, İrfan},
title = {Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae125}
}
EUVIMED